New combo therapy aims to halt liver tumors in patients with advanced neuroendocrine cancer

NCT ID NCT04339036

First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 19 times

Summary

This study tests whether adding a type of internal radiation (Yttrium-90) to a standard chemotherapy regimen (Capecitabine and Temozolomide) can better control neuroendocrine tumors that have spread to the liver and cannot be surgically removed. About 70 adults with grade 2 or 3 disease will receive the combination therapy. The goal is to see if this approach delays tumor growth in the liver more than either treatment alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Roswell Park Comprehensive Cancer Center

    RECRUITING

    Buffalo, New York, 14203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UC San Diego

    RECRUITING

    La Jolla, California, 92037, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19103, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.